Artemisinin nanoformulation suitable for intravenous injection: Preparation, characterization and antimalarial activities

International Journal of Pharmaceutics

Volumn 495, Issue 2, 2015, Pages 671-679

  Ibrahim, Nehal ^a   Ibrahim, Hany ^a   Sabater, Alicia Moreno ^b,c,d   Mazier, Dominique ^b,c,d,e   Valentin, Alexis ^a   Nepveu, Françoise ^a  

^a Hôpital Purpan   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d Assistance publique Hôpitaux de Paris   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Albumin; Artemisinin; High pressure homogenization; Intravenous injection; Malaria; Nanoparticles

Indexed keywords

ALBUMIN; ARTEMISININ; NANOPARTICLE; ORGANIC SOLVENT; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ANTIMALARIAL ACTIVITY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ERYTHROCYTE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALARIA, FALCIPARUM; MOUSE; NONOBESE DIABETIC MOUSE; PARASITEMIA; PARASITOLOGY; PLASMODIUM FALCIPARUM; SCID MOUSE; SOLUBILITY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; INJECTIONS, INTRAVENOUS; MALARIA, FALCIPARUM; MICE; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; PARASITEMIA; PARTICLE SIZE; PLASMODIUM FALCIPARUM; SOLUBILITY;

EID: 84944351187     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.09.020     Document Type: Article

References (59)

1. W. Abdelwahed, G. Degobert, S. Stainmesse, and et al. Freeze-drying of nanoparticles: formulation, process and storage considerations Adv. Drug Deliv. Rev. 58 2006 1688 1713
2. A. Benakis, M. Paris, L. Loutan, and et al. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers Am. J. Trop. Med. Hyg. 56 1997 17 23
3. H. Bian, M. Li, Q. Yu, and et al. Study of the interaction of artemisinin with bovine serum albumin Int. J. Biol. Macromol. 39 2006 291 297
4. E. Chambers, and S. Mitragotri Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes J. Control. Release 100 2004 111 119
5. D. Chaturvedi, A. Goswami, P.P. Saikia, and et al. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents Chem. Soc. Rev. 39 2010 435 454
6. W. Chen, B. Gu, H. Wang, and et al. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles Int. J. Pharm. 362 2008 133 140
7. L. Chunlei, L. Yanhui, G. Yuqing, and et al. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous? Int. J. Pharm. 468 2014 15 25
8. L. Cui, and X.Z. Su Discovery, mechanisms of action and combination therapy of artemisinin Exp. Rev. Anti. Infect. Ther. 7 2009 999 1013
9. N. Desai, V. Trieu, Z. Yao, and et al. Increased antitumor activity, intratumor paclitaxel concentrations and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res. 12 2006 1317 1324
10. S.J. Douglas, S.S. Davis, and L. Illum Nanoparticles in drug delivery Crit. Rev. Ther. Drug Carrier Syst. 3 1987 233 261
11. C. Duranton, V. Tanneur, C. Lang, and et al. A high specificity and affinity interaction with serum albumin stimulates an anion conductance in malaria-infected erythrocytes Cell Physiol. Biochem. 22 2008 395 404
12. T. Efferth, M.R. Romero, D.G. Wolf, and et al. The antiviral activities of artemisinin and artesunate Clin. Infect. Dis. 47 2008 804 811
13. T. Efferth Willmar schwabe award 2006 antiplasmodial and antitumor activity of artemisinin: from bench to bedside Planta Med. 73 2007 299 309
14. A. El Tahir, P. Malhorta, and V.S. Chauhan Uptake of proteins and degradation of human serum albumin by Plasmodium falciparum-infected erythrocytes Malaria J. 2 2003 11
15. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
16. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
17. H. Fessi, J.P. Devissaguet, and F. Puisieux Procédés de préparation de systèmes colloïdaux dispersibles d'une substance sous forme de nanocapsules Brevet Français 1986 8618444
18. T. Gordi, D.X. Huong, T.N. Hai, and et al. Artemisinin pharmacokinetics and efficacy in uncomplicated malaria patients treated with two different dosage regimens Antimicrob. Agents Chemother. 46 2002 1026 1031
19. A. Hawe, and W. Freiss Physicochemical characterization of the freezing behavior of mannitol-human serum albumin formulations AAPS PharmSciTech 7 2006 94
20. W.E. Ho, H.Y. Peh, T.K. Chan, and et al. Artemisinins: pharmacological actions beyond anti-malarial Pharmacol. Ther. 142 2014 126 139
21. N. Ibrahim, H. Ibrahim, J. Dormoi, and et al. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy Int. J. Pharm. 464 2014 214 224
22. T. Ishihara, M. Takahashi, M. Higaki, and et al. Prolonging the in vivo residence time of Prostaglandin E1 with biodegradable nanoparticles, Pharm Res. 7 2008 1686 1695
23. T.A. John, S.M. Vogel, C. Tiruppathi, and et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer Am. J. Physiol. Lung Cell Mol. Physiol. 284 2003 187 196
24. C.C. John, E. Kutamba, K. Mugarura, and et al. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria Exp. Rev. Anti. Infect. Ther. 8 2010 997 1008
25. H.A. Karunajeewa, L. Manning, I. Mueller, and et al. Rectal administration of artemisinin derivatives for the treatment of malaria JAMA 297 2007 2381 2390
26. Kipp J.E., Wong J.C.T., Doty M.J., et al., 2003. Microprecipitation method for preparing submicron suspensions, U.S. Patent 6,607,784.
27. D. Klayman Qinghaosu (artemisinin): an antimalarial drug from China Science 228 1985 1049 1055
28. R. Koopmans, L.D. Ha, D.D. Duc, and et al. The pharmacokinetics of artemisinin after administration of two different suppositories to healthy Vietnamese subjects Am. J. Trop. Med Hyg. 60 1999 244 247
29. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
30. S. Krishna, L. Bustamante, R.K. Haynes, and et al. Artemisinins: their growing importance in medicine Trends Pharmacol. Sci. 29 2008 520 527
31. N. Kumar, and H. Zheng Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum Paraditol. Res. 76 1990 214 218
32. J.C. Kwok, and D.R. Richardson The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hematol. 42 2002 65 78
33. V.D. Labhasetwar, and A.K. Dorle Nanoparticles - a colloidal drug delivery system for metronidazole and primaquine J. Control. Release 12 1990 113 119
34. A.J. Lin, D.L. Klayman, and W.K. Milhous Antimalarial activity of new water-soluble dihydroartemisinin derivatives J. Med. Chem. 30 1987 2147 2450
35. H. Ménan, J.T. Banzouzi, A. Hocquette, and et al. Antiplasmodial activity and cytotoxicity of plants used in West African traditional medicine for the treatment of malaria J. Ethnopharmacol. 105 2006 131 136
36. J. May, and C.G. Meyer Chemoresistance in falciparum malaria Trends Parasitol 19 2003 432 435
37. A. Moreno, E. Ferrer, S. Arahuetes, and et al. The course of infections and pathology in immunomodulated NOD/LtSz-SCID mice inoculated with Plasmodium falciparum laboratory lines and clinical isolates Int. J. Parasitol. 36 2006 361 369
38. V.C.F. Mosqueira, P.M. Loiseau, C. Bories, and et al. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice Antimicrob. Agents Chemother. 48 2004 1222 1228
39. R.H. Muller, and J.U. Junghanns Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs V.P. Torchilin, Nanoparticulates as Drug Carriers 2006 Imperial College Press London 307 313
40. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170
41. F. Nepveu, S. Kim, J. Boyer, and et al. Synthesis and antiplasmodial activity of new indolone N-oxide derivatives J. Med. Chem. 53 2010 699 714
42. S. Patil, M. Joshi, S. Pathak, and et al. Intravenous β-artemether formulation (ARM-NLC) as a superior alternative to commercial artesunate formulation J. Antimicrob. Chemother. 67 2012 2713 2716
43. S.A. Payghan, and M. Bhat Albumin microspheres containing artemisinin Pharmacist 3 2008 33 36
44. P.L. Porter, E.H. Sage, T.F. Lane, and et al. Distribution of SPARC in normal and neoplastic human tissue J. Histochem. Cytochem. 43 1995 791 800
45. R. Price, M. Van Vugt, L. Phaipun, and et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives Am. J. Trop. Med. Hyg. 60 1999 547 555
46. R.G. Ridley Medical need, scientific opportunity and the drive for antimalarial drugs Nature 415 2002 686 693
47. A. Saupe, S.A. Wissing, A. Lenk, and et al. Solid lipid nanoparticles (SLN) and nanostructured lipid Ccarriers (NLC) - structural investigations on two different carrier systems Bio-Med. Mater. Eng. 15 2005 393 402
48. Y. Shujuan, Z. Hongling, P. Junyan, and et al. Studies on the preparation, characterization and intracellular kinetics of JD27-loaded human serum albumin nanoparticles Proc. Eng. 102 2015 590 601
49. E.A. Simone, T.D. Dziubla, and V.R. Muzykantov Polymeric carriers: role of geometry in drug delivery Exp. Opin. Drug Deliv. 5 2008 1283 1300
50. K. Ter, F. uile, N.J. White, P. Holloway, and et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria Exp. Parasitol. 76 1993 85 95
51. E.C. Unger, R. Zutshi, T.O. Matsunaga, and et al. Lipid-coated submicron-sized particles as drug carriers V.P. Torchilin, Nanoparticulates as Drug Carriers 2006 Imperial College Press London p. 226
52. J. Utzinger, S.H. Xiao, M. Tanner, and et al. Artemisinins for schistosomiasis and beyond Curr. Opin. Invest. Drugs 8 2007 105 116
53. R. Van, N. ooijen, and A. Sanders Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications J. Immunol. Methods 174 1994 83 93
54. J.L. Vennerstrom, S. Arbe-Barnes, R. Brun, and et al. Identification of an antimalarial synthetic trioxolane drug development candidate Nature 430 2004 900 904
55. C. Weber, C. Coester, J. Kreuter, and et al. Desolvation process and surface characteristics of protein nanoparticles Int. J. Pharm. 194 2000 91 102
56. T.N.C. Wells, P.L. Alonso, and W.E. Gutteridge New medicines to improve control and contribute to the eradication of malaria Nat. Rev. Drug Discov. 8 2009 879 891
57. N.J. White Qinghaosu (artemisinin): the price of success Science 320 2008 330 334
58. C.J. Whitty, and F. Sanderson New therapies and changing patterns of treatment for malaria Curr. Opin. Infect. Dis. 12 1999 579 584
59. C.J. Woodrow, R.K. Haynes, and S. Krishna Artemisinins Postgrad. Med. J. 81 2005 71 78